OncoSec Medical Inc., a company developing advanced-stage technologies to treat solid tumor cancers, was granted a new patent from China.
The San Diego-based biopharmaceutical company (OTCBB: ONCS) scored a new Method of Use and Device patent for the OncoSec Medical System (OMS) electroporation device platform from the State Intellectual Property Office of the People's Republic of China.
The issuance of this patent has the potential to expand OncoSec's commercial opportunities for minimally invasive and surgical procedures to treat solid tumors in a very large market such as China.
"This patent will act as a part of the company's core strategy as we continue to develop and build our commercialization strategy in China, one of the largest emerging oncology markets," said Punit Dhillon, OncoSec's president and CEO.
Numerous research studies have concluded that cancer has now become a leading cause of mortality in China, representing 25 percent of all deaths in urban areas and 21 percent in rural areas.
The company's ImmunoPulse and NeoPulse therapies are being evaluated to reduce the rate of cancer recurrence while minimizing quality-of-life side effects.
The approaches involve injecting the tumor with an anti-cancer agent, followed by electroporation to open up the cell membrane, which helps significantly increase the uptake of the agent.
4690 Executive Dr. Ste., 250
San Diego, CA 92121